Curocell Inc. (KOSDAQ:372320)

Market Cap	686.79B +63.4%
Revenue (ttm)	n/a
Net Income	-39.26B
EPS	-2,755.02
Shares Out	14.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,342
Average Volume	130,519
Open	47,500
Previous Close	49,250
Day's Range	46,250 - 48,800
52-Week Range	23,750 - 58,100
Beta	1.40
RSI	47.87
Earnings Date	Mar 13, 2026

About Curocell

Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 372320